All Stories

  1. Temporal trends and clinical characteristics of drug-coated balloon angioplasty for de novo coronary lesions: A 6-year analysis from the ORPKI registry
  2. Lower Attained Scores, No Evidence of Less Improvement
  3. Angina Severity in Severe Aortic Stenosis with a Single Intermediate Left Anterior Descending Artery Lesion: Associations with Measured Aortic Valve Area and Epicardial Pressure-Derived Indices
  4. Clinical Characteristics and Invasive Management of Acute Myocardial Infarction in the Post–COVID-19 Era
  5. Sex Discordance and PCI Outcomes: Marker of Disparity Rather Than Mechanism
  6. Sex disparities in STEMI care: pre-hospital delay and acute heart failure
  7. Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes
  8. Distribution of lipoprotein(a) and its association with atherosclerotic cardiovascular disease in a large real-world Polish cohort
  9. Temporal Trends and Clinical Characteristics of Incretin‐Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real‐World Cohort Study From a Polish Private Healthcare Network
  10. Letter to the Editor “Phenotypic and Structural Granularity in Cardiogeriatric Risk Stratification” regarding: “Cardiovascular Disease, Frailty, and Multimorbidity as Predictors of Adverse Outcomes in Older Adults Admitted to Acute Geriatric Settings: ...
  11. Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review
  12. Coronary Flow Reserve in Adults: Pathophysiology, Assessment Modalities, Clinical Applications, and Prognostic Significance
  13. Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland
  14. Sirolimus-Coated Balloons in the Metal-Free Registry: Favorable Outcomes, Unaddressed Contemporary Standards
  15. Semaglutide in Frail HFpEF
  16. The paradox of increasing cardiac amyloidosis hospitalizations and persistent diagnostic delays
  17. Correspondence on: Impact of coronary artery disease patterns assessed with pullback pressure gradient on clinical outcomes: Meta-analysis
  18. Cardiometabolic Profiles and Treatment Trajectories of GLP ‐1 Receptor Agonist Users With Obstructive Sleep Apnea: Real‐World Evidence From a Large Private Healthcare Cohort in Poland
  19. Diabetes-Related Differences in the Predictive Value of the Physiological Assessment of Myocardial Ischemia for Long-Term Clinical Outcomes
  20. Proactive Surveillance for ICI Cardiotoxicity
  21. Albumin-Bilirubin Score for Contrast-Induced Acute Kidney Injury Prediction in STEMI: Critical Limitations
  22. The Red Cell Distribution Width/Albumin Ratio in STEMI: Biologically Plausible but Clinically Unproven
  23. A Critical Appraisal of Troponin as a Prognostic Biomarker in Stable Supraventricular Tachycardia: Contextualizing Recent Findings
  24. From Pathophysiology to Etiology
  25. The Siren Song of the Chatbot: Persuasive Hallucinations and Automation Bias in OMI Detection
  26. Pathogenesis of Acute Coronary Syndromes in Patients After COVID-19: An Optical Coherence Tomography Study
  27. Prolonged occlusion flow-mediated dilation for radial artery cannulation: Where does it fit in modern practice?
  28. The Irreversible March of Time: Ischemic Delay and Impact on Outcomes in ST-Segment Elevation Myocardial Infarction
  29. The galectin-3/NLRP3 inflammasome axis: A unifying mechanism linking insomnia and heart failure
  30. DOACs for Left Ventricular Thrombus: Persistent Equipoise Despite New Observational and Randomized Data
  31. The Pullback Pressure Gradient: Transforming Invasive Coronary Physiology from Lesion Assessment to Disease Pattern Characterization—A Perspective
  32. Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland
  33. Novel therapies for lowering low-density lipoprotein levels for atherosclerotic cardiovascular disease prevention: reaching the target where others have failed
  34. Inflammation as a Foundational Cardiovascular Risk Factor: Limitations and Context of the Zuo et al. Study
  35. Long-Term Outcomes After Myocardial Infarction in Young Adults: The Unseen Impact of Delays, Nonatherosclerotic Factors, and Subgroup Vulnerabilities
  36. A call for caution: interpreting myocardial infarction outcomes in inflammatory joint disease
  37. Age-related sex differences in intensive care treatment and outcomes. Comment on Br J Anaesth 2025
  38. The First Ten Minutes: Sex Disparities in Myocardial Infarction Begin at the Door
  39. Letter to the editor: “Structured team response and sex-based mortality gaps in acute pulmonary embolism: Conflicting evidence and future directions”
  40. The Irreversible March of Time: Ischemic Delay and Impact on Outcomes in ST-Segment Elevation Myocardial Infarction
  41. High Post–Transcatheter Aortic Valve Replacement Gradients: Not a Direct Predictor of Valve Deterioration
  42. Persistently low initiation of GLP-1 receptor agonists for weight management in individuals without diabetes in Poland: a major unmet need
  43. Addressing gender disparities in cardiovascular care: insights from the Polish national clinical registry
  44. Distinct clinical phenotypes of delirium in the cardiac intensive care unit: Moving beyond a single diagnostic entity
  45. Managing Acute Coronary Syndromes in Older Adults: Challenges and Registry Insights
  46. Regarding “Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events”: a compelling hypothesis warranting cautious interpretation
  47. Anthracyclines as diagnostic stressors: mitophagy signaling and hidden cardiac vulnerability
  48. Beyond traditional risk factors: the need for comprehensive phenotyping in young acute myocardial infarction patients
  49. Context-dependent nature of the obesity paradox in cardiac events
  50. Microvascular Function and Discordance in Physiology‐Guided PCI: Correlation or Causation?
  51. Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk
  52. In-Hospital Levels of Circulating MicroRNAs as Potential Predictors of Left Ventricular Remodeling Post-Myocardial Infarction
  53. The Impact of Age on the Physiological Assessment of Borderline Coronary Stenoses
  54. Comparison of Fractional Flow Reserve with Resting Non-Hyperemic Indices in Patients with Coronary Artery Disease
  55. Impact of COVID-19 Pandemic on Patients with ST-Segment-Elevation Myocardial Infarction Complicated by Out-of-Hospital Cardiac Arrest
  56. Knowledge and Prevalence of Risk Factors for Coronary Artery Disease in Patients after Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting
  57. Frailty as a Predictor of In-Hospital Outcome in Patients with Myocardial Infarction
  58. Safety and Efficacy of Four Different Diagnostic Catheter Curves Dedicated to One-Catheter Technique of Transradial Coronaro-Angiography—Prospective, Randomized Pilot Study. TRACT 1: Trans RAdial CoronaryAngiography Trial 1
  59. Balloon Aortic Valvuloplasty for Severe Aortic Stenosis as Rescue or Bridge Therapy
  60. Treatment Delay and Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction during the COVID-19 Pandemic
  61. Percutaneous coronary intervention during on- and off-hours in patients with ST-segment elevation myocardial infarction
  62. The Usefulness of [18F]F-Fluorodeoxyglucose and [18F]F-Sodium Fluoride Positron Emission Tomography Imaging in the Assessment of Early-Stage Aortic Valve Degeneration after Transcatheter Aortic Valve Implantation (TAVI)—Protocol Description and Prelimi...
  63. Direct Rapid Left Ventricular Wire Pacing during Balloon Aortic Valvuloplasty
  64. Calcium Pattern Assessment in Patients with Severe Aortic Stenosis Via the Chou’s 5-Steps Rule
  65. Prevalence and Predictors of Coronary Artery Perforation During Percutaneous Coronary Interventions (from the ORPKI National Registry in Poland)
  66. Radial Approach Expertise and Clinical Outcomes of Percutanous Coronary Interventions Performed Using Femoral Approach
  67. Hypertrophic Cardiomyopathy: The Time-Synchronized Relationship between Ischemia and Left Ventricular Dysfunction Assessed by Highly Sensitive Troponin I and NT-proBNP
  68. Hospitalization Length after Myocardial Infarction: Risk-Assessment-Based Time of Hospital Discharge vs. Real Life Practice
  69. Association of Inadequately Low Left Ventricular Mass with Enhanced Myocardial Contractility in Severe Degenerative Aortic Stenosis
  70. Safety of FFR-guided revascularisation deferral in Anatomically prognostiC diseasE (FACE: CARDIOGROUP V STUDY): A prospective multicentre study
  71. Impact of On-Site Surgical Backup on Periprocedural Outcomes of Primary Percutaneous Interventions in Patients Presenting With ST-Segment Elevation Myocardial Infarction (From the ORPKI Polish National Registry)
  72. Impact of Pre-procedural Cerebrovascular Events on Clinical Outcomes After Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis
  73. Impact of chronic obstructive pulmonary disease and frailty on long-term outcomes and quality of life after transcatheter aortic valve implantation
  74. Predictors of in-hospital effectiveness and complications of rotational atherectomy (from the ORPKI Polish National Registry 2014-2016)
  75. In-hospital and long-term outcomes of percutaneous balloon aortic valvuloplasty with concomitant percutaneous coronary intervention in patients with severe aortic stenosis
  76. An interesting case of a self-apposing stent implantation in an aneurysmatically dilated artery in acute myocardial infarction with high quality optical coherence tomography images
  77. Determinants of stroke following percutaneous coronary intervention in acute myocardial infarction (from ORPKI Polish National Registry)
  78. The impact of multiple stent implantation in the infarct-related artery on one-year clinical outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Data from the Polish NRDES Registry
  79. Acute and long-term outcomes of percutaneous balloon aortic valvuloplasty for the treatment of severe aortic stenosis
  80. Decreased carotid and vertebral arterial blood-flow velocity in response to orthostatic unload in patients with severe aortic stenosis
  81. Twelve-Month Quality of Life Improvement and All-Cause Mortality in Elderly Patients Undergoing Transcatheter Aortic Valve Replacement
  82. Impact of Coronary Artery Disease Burden on 12-Month Mortality of Patients After Transcatheter Aortic Valve Implantation
  83. Assessment of quality of life in patients after surgical and transcatheter aortic valve replacement
  84. Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland
  85. Early- and mid-term outcomes after transcatheter aortic valve implantation. Data from a single-center registry
  86. Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation
  87. No clinical benefit from manual thrombus aspiration in patients with non-ST-elevation myocardial infarction
  88. Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014–2015
  89. The successful retrieval of a broken guide wire from the diagonal branch of the left anterior descending coronary artery complicated by partial stent rolling
  90. Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non–ST-Elevation Myoc...
  91. A 24-year-old male with acute coronary syndrome due to the circumflex coronary artery thrombosis. Diagnostic challenge in everyday practice
  92. A response to “The importance of vasodilator therapy before or during angiography, is ICD necessary or not?” by Tamer Kırat and Nuri Köse
  93. Effect of introducing a regional 24/7 primary percutaneous coronary intervention service network on treatment outcomes in patients with ST segment elevation myocardial infarction
  94. Impact of coronary artery disease presence on the long-term follow-up of carotid artery stenting
  95. Recurrent coronary vasospasm-induced acute coronary syndrome complicated by cardiac arrest
  96. Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction
  97. Complete infarct-related artery revascularization in acute myocardial infarction patients. CORAMI Registry
  98. Images in intervention Transradial percutaneous coronary intervention for unprotected left main closure during acute myocardial infarction
  99. Efficacy of an Embolic Protection Stent as a Function of Delay to Reperfusion in ST-Segment Elevation Myocardial Infarction (from the MASTER Trial)
  100. Similar outcome of ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention regardless of presence of cardiac surgery on-site
  101. Impact of direct stenting on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER registry)
  102. Short- and intermediate-term improvement of patient quality of life after transcatheter aortic valve implantation: a single-centre study
  103. Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectives
  104. No long-term clinical benefit from manual aspiration thrombectomy in ST-elevation myocardial infarction patients. Data from NRDES registry
  105. Authors’ response
  106. Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction
  107. Impact of intra-aortic balloon pump on long-term mortality of unselected patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock
  108. Primary Angioplasty in Patient with St-Segment Elevation Myocardial Infarction in the Setting of Intentional Carbon Monoxide Poisoning
  109. Ultrasound-guided thrombin injection in the treatment of iatrogenic arterial pseudoaneurysms: Single-center experience
  110. Patient with non-ST-segment elevation myocardial infarction treated by Absorb bioresorbable scaffold implantation
  111. Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry
  112. Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty
  113. Acute left main occlusion during transcatheter aortic valve implantation
  114. Acute myocardial infarction in a patient with chronic renal failure and endocarditis
  115. Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience
  116. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial
  117. Cardioembolic acute myocardial infarction and stroke in a patient with persistent atrial fibrillation
  118. Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
  119. Inverted takotsubo cardiomyopathy in a patient with essential thrombocythemia exposed to anagrelide and phentermine
  120. Use of aspiration thrombectomy in a 102-year-old patient with acute inferior ST-segment elevation myocardial infarction
  121. Successful primary angioplasty in patient with ST-segment elevation myocardial infarction caused by large septal branch occlusion
  122. Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
  123. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry)
  124. Age-related differences in treatment strategies and clinical outcomes in unselected cohort of patients with ST-segment elevation myocardial infarction transferred for primary angioplasty
  125. Out-of-hospital cardiac arrest in patients treated with primary PCI for STEMI. Long-term follow up data from EUROTRANSFER registry
  126. Evidence for mesh-covered stent implantation in ST-segment elevation myocardial infarction
  127. Tools & Techniques: PCI for acute MI tips and tricks
  128. Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome
  129. Taxcor for the prevention of restenosis. Polish multicentre observational study to assess the efficacy and safety of the Genius TAXCOR I stent
  130. Thrombus aspiration followed by direct stenting: A novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish-Italian-Hungarian RAndomized ThrombEctomy Trial (PIHRATE Trial)
  131. Mesh covered stent in ST-segment elevation myocardial infarction
  132. Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry
  133. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in elderly patients transferred with ST-elevation myocardial infarction
  134. Impact of Multivessel Coronary Artery Disease and Noninfarct-Related Artery Revascularization on Outcome of Patients With ST-Elevation Myocardial Infarction Transferred for Primary Percutaneous Coronary Intervention (from the EUROTRANSFER Registry)
  135. Transradial approach in patients with ST-elevation myocardial infarction treated with abciximab results in fewer bleeding complications: data from EUROTRANSFER registry
  136. Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction
  137. Angiographic perfusion score assessed in patients with acute myocardial infarction is correlated with cardiac magnetic resonance infarct size and N-terminal pro-brain natriuretic peptide in 6-month follow-up
  138. Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention
  139. Transportation with very long transfer delays (>90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction
  140. Predictors and in-hospital outcomes of cardiogenic shock on admission in patients with acute coronary syndromes admitted to hospitals without on-site invasive facilities
  141. Long-term follow-up of percutaneous peripheral interventions in lower limb arteries in patients with acute coronary syndrome and diabetes
  142. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
  143. Impact of Admission Glucose Level and Presence of Diabetes Mellitus on Mortality in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Treated Conservatively
  144. ST-segment resolution assessed immediately after primary percutaneous coronary intervention correlates with infarct size and left ventricular function in cardiac magnetic resonance at 1-year follow-up
  145. PCI after lytic therapy: when and how?
  146. Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome
  147. Time delay in primary angioplasty: how relevant is it?
  148. More aggressive pharmacological treatment may improve clinical outcome in patients with non-ST-elevation acute coronary syndromes treated conservatively
  149. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: A randomized study
  150. Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
  151. The role of thrombectomy and embolic protection devices
  152. Facilitated percutaneous coronary intervention in patients with acute myocardial infarction transferred from remote hospitals